Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb 10:64:247-256.
doi: 10.2340/1651-226X.2025.42314.

Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II)

Pia J Heino  1 , Jukka Pappinen  2 , John F Thompson  3 , Micaela Hernberg  4 , Tiina A Jahkola  5 , Mark B Faries  6
Affiliations
Randomized Controlled Trial

Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II)

Pia J Heino et al. Acta Oncol. .

Abstract

Background and purpose: After reports that complete lymph node dissection (CLND) did not improve melanoma-specific survival of sentinel lymph node (SLN)-positive patients, the use of CLND has diminished but it is still carried out for selected patients. We sought to assess differences in Health-Related Quality of Life (HRQoL) and tertiary care costs among the Finnish Multicenter Selective Lymphadenectomy Trial (MSLT)-II-patients.

Patients/materials and methods: A total of 52 patients randomized to CLND and 55 to nodal observation completed a modified version of the standardized and validated, RAND-36 questionnaire at baseline, 4 months and annually up to 5 years. Tertiary care costs between the groups were also compared.

Results: At 60 months, the mean HRQoL score for the CLND and observation groups for General Health were 77.3 versus 65.0 (p = 0.007, adjusted p = 0.065), for role limitations due to physical health 89.5 versus 72.3 (p = 0.029, adjusted p = 0.203) and for role limitations due to emotional problems 91.4 versus 71.9 (p = 0.006, adjusted p = 0.065) and at 48 months, 92.8 versus 71.3 (p = 0.002, adjusted p = 0.056). Median costs per patient were higher in the CLND group at 4 months but the difference disappeared during follow-up.

Interpretation: This study suggests that undergoing CLND after a positive SLN biopsy is not a predictor of worse HRQoL. CLND generates greater costs initially, but there seem to be no major differences in total cost per patient between the two groups.

PubMed Disclaimer

Conflict of interest statement

M.B.F. has the following conflicts of interest to disclose: Advisory Boards: Bristol Myers Squbb, Merck, Novartis, Instil Bio, Regeneron, Delcath Systems. J.F.T. has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Biopharmaceuticals, and conference and travel support from GSK and Provectus Biopharmaceuticals.

Figures

Figure 1
Figure 1
General health mean scores.
Figure 2
Figure 2
Physical functioning mean scores.
Figure 3
Figure 3
Role limitations due to physical health mean scores.
Figure 4
Figure 4
Role limitations due to emotional problems mean scores.
Figure 5
Figure 5
Median costs and IQR*. *IQR: interquartile range
Figure 6
Figure 6
Distribution of costs per patient.
See this image and copyright information in PMC

References

    1. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–222. 10.1056/NEJMoa1613210 - DOI - PMC - PubMed
    1. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67. 10.1016/S1470-2045(16)00141-8 - DOI - PubMed
    1. Leonard LD, Beaty L, Thomas M, Quinn C, Colborn KL, de Araujo TB, et al. Unmeasured factors are associated with the use of completion lymph node dissection (CLND) in melanoma. J Surg Oncol. 2023;127(4):716–26. 10.1002/jso.27153 - DOI - PubMed
    1. Bredbeck BC, Mubarak E, Zubieta DG, Tesorero R, Holmes AR, Dossett LA, et al. Management of the positive sentinel lymph node in the post-MSLT-II era. J Surg Oncol. 2020;122(8):1778–84. 10.1002/jso.26200 - DOI - PMC - PubMed
    1. Wrightson WR, Wong SL, Edwards MJ, Chao C, Reintgen DS, Ross MI, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10(6):676–80. 10.1245/ASO.2003.10.001 - DOI - PubMed

Publication types

LinkOut - more resources